Health

supply for several years (major unrelated fungal outbreak in India and supply chain issues).

And then there are resistance issues...
Many of the classes of antifungals may still work (Amphotericin B, Fluconazole and other triazoles, and the Echinocandin class drugs) but at levels that dramatically increase toxicity. That said some isolates have been found to be highly resistant to all three classes removing any remaining options.

Research on new antifungal drugs has languished, not only because of the pandemic COVID and other emerging viruses but because of the critical nature of bacterial resistance requiring a considerable emphasis on creating new antibacterial agents.

And THIS, at a time when we have such anti-science attitudes in Congress that $$$ for R&D at NIH and through grants to academic centers is quite an uphill battle.

Those of us in medicine see the acuity of the problem but will anyone listen?